Budget season is in full swing at firms whose fiscal year matches the calendar year, and leaders are exercising a newfound scrutiny over every component of next year’s spending as they prepare for an uncertain 2021.

After cutting expenses in the early months of the pandemic, firms were rewarded by better than anticipated demand, and many are anticipating quite healthy numbers in 2020. But even with optimism rising over Pfizer’s promising COVID-19 vaccine, that careful approach to expenditures is bound to continue.